Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19

Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19

Background In China, both nirmatrelvir-ritonavir (Paxlovid) and azvudine have been granted approval to treat adult SARS-CoV-2-infected patients with moderate symptoms. Information about the clinical effect of the two available agents among inpatients with severe or critical COVID-19 is scarce.Purpos...

Full description

Bibliographic Details
Main Authors: Junjun Chen, Zheng Zhang, Huan Zhang, Yao Li, Yan Kang, Jianbo Li, Tan Xiaojiao, Chenxi Wang, Haiqing Shi, Xiaodong Jin, Xuelian Liao
Format: Article
Language:English
Published: BMJ Publishing Group 2024-04-01
Series:BMJ Open Respiratory Research
Online Access:https://bmjopenrespres.bmj.com/content/11/1/e001944.full

Internet

https://bmjopenrespres.bmj.com/content/11/1/e001944.full

Similar Items